Exosomes are skincare’s hottest trend — the FDA says none are approved, and it just warned clinics selling them

Exosomes — tiny vesicles sold on promises of firmer skin, thicker hair, and “cellular rejuvenation” — are one of beauty’s biggest trends, boosted by celebrity endorsements. But in August 2026, the FDA sent warning letters to clinics marketing them, for false product claims and manufacturing failures. Here’s what the agency did, what exosomes actually are, and how to read a “cellular rejuvenation” claim with clear eyes.

What did the FDA actually do?

The FDA issued warning letters in August 2026 to clinics — including R3 Medical Companies — over exosome products, citing false product claims and manufacturing failures, according to reporting on October 5. The key fact: no exosome products are FDA-approved. Period.

This isn’t the agency’s first move. The FDA issued a public safety notification against unapproved exosome treatments back in 2019. This summer’s letters are a repeat crackdown — a sign the agency thinks the market ignored the first warning.

What are exosomes — and why is everyone talking about them?

Exosomes are tiny vesicles shed by cells — including human stem cells — that carry lipids, proteins, and bits of genetic material between cells. Clinics market them to speed cell turnover, firm skin, fade hyperpigmentation, and thicken hair. The pitch got louder with celebrity endorsements from figures like Kim Kardashian and Melissa Gorga.

The science underneath is genuinely interesting: early research is exploring exosomes in Alzheimer’s, osteoarthritis, and spinal cord injury. But early research is not a product — and as triple board-certified cosmetic surgeon Dr. Gina Maccarone told USA Today, “when a product is poorly characterized, you can’t fully predict its side effects because you don’t reliably know what’s in it.” Most published data comes from small, short-duration studies with no years-long follow-up.

How to read a “cellular rejuvenation” claim

This is the same claim family as many mitochondrial therapies — “rejuvenate your cells” — so the discipline transfers directly. Before you believe a cell-therapy pitch, ask: what exactly is in the product, how was it manufactured, who administers it, and is there a registered clinical trial behind the claims? If the answers are vague, the claims should be too.

The watchdog principle: promising biology plus absent evidence equals marketing ahead of medicine. Exosome research may one day deliver real therapies. Today, every product on the market is ahead of the proof.

Where the evidence stands

• Established: FDA warning letters to exosome-selling clinics (August 2026); no exosome products are FDA-approved; a 2019 FDA safety notification against unapproved exosome treatments.
• Preliminary: Early exosome research in Alzheimer’s, osteoarthritis, and spinal cord injury — promising biology, not established therapy.
• Absent: Evidence for the marketed cosmetic claims; long-term safety data for clinic-sold exosome products.